Clinical trial
Atomoxetine for Children With Acquired Attentional Disorders Following…
NCT00299234 · Monarch Medical Research, Other · Terminated
Key facts
| NCT number | NCT00299234 |
|---|---|
| Title | Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL |
| Official title | Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia |
| Lead sponsor | Monarch Medical Research, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | Atomoxetine |
| Enrollment | 1 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Mar 6, 2006 |
| Last update posted | Apr 26, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: